Jia Zhu

Jia Zhu

Auto-generated profile, based on publicly available information

Jia Zhu

Division of Endocrinology, Department of Pediatrics, Boston Children's Hospital , Boston, MA 02115

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
JZJia Zhu
Jia Zhu
FEFlorian Eichler
Florian Eichler
ABAlessandra Biffi
Alessandra Biffi
CDChristine N Duncan
Christine N Duncan
DWDavid A Williams
David A Williams
JMJoseph A Majzoub
Joseph A Majzoub
Adrenoleukodystrophy (ALD) is a rare X-linked disorder of peroxisomal oxidation due to mutations in ABCD1. It is a progressive condition with a variable clinical spectrum that includes primary adrenal insufficiency, myelopathy, and cerebral ALD. Adrenal insufficiency affects over 80% of ALD patients. Cerebral ALD affects one-third of boys under the age of 12 and progresses to total disability and death without treatment. Hematopoietic stem cell transplantation (HSCT) remains the only disease-modifying therapy if completed in the early stages of cerebral ALD, but it does not affect the course of adrenal insufficiency. It has significant associated morbidity and mortality. A recent gene therapy clinical trial for ALD reported short-term MRI and neurological outcomes comparable to historical patients treated with HSCT without the associated adverse side effects. In addition, over a dozen states have started newborn screening (NBS) for ALD, with the number of states expecting to double in 2020. Genetic testing of NBS-positive neonates has identified novel variants of unknown significance, providing further opportunity for genetic characterization but also uncertainty in the monitoring and therapy of subclinical and/or mild adrenal insufficiency or cerebral involvement. As more individuals with ALD are identified at birth, it remains uncertain if availability of matched donors, transplant (and, potentially, gene therapy) centers, and specialists may affect the timely treatment of these individuals. As these promising gene therapy trials and NBS transform the clinical management and outcomes of ALD, there will be an increasing need for the endocrine management of presymptomatic and subclinical adrenal insufficiency. (Endocrine Reviews 41: 1 – 17, 2020) Graphical Abstract Open in new tab Download slide

19 November 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
JZJia Zhu
Jia Zhu
NPNatàlia Pujol-Gualdo
Natàlia Pujol-Gualdo
LWLaura B L Wittemans
Laura B L Wittemans
CLCecilia Lindgren
Cecilia Lindgren
TLTriin Laisk
Triin Laisk
YCYee-Ming Chan
Yee-Ming Chan
Context Polycystic ovary syndrome (PCOS) is characterized by ovulatory dysfunction and hyperandrogenism and can be associated with cardiometabolic dysfunction, but it remains unclear which of these features are inciting causes and which are secondary consequences. Objective To determine whether ovarian function is necessary for genetic risk factors for PCOS to produce nonreproductive phenotypes. Design, Setting, and Participants Cohort of 176 360 men in the UK Biobank and replication cohort of 37 348 men in the Estonian Biobank. Main Outcome Measures We calculated individual PCOS polygenic risk scores (PRS), tested for association of these PRS with PCOS-related phenotypes using linear and logistic regression and performed mediation analysis. Results For every 1 SD increase in the PCOS PRS, men had increased odds of obesity (odds ratio [OR]: 1.09; 95% CI, 1.08-1.10; P = 1 × 10-49), type 2 diabetes mellitus (T2DM) (OR: 1.08; 95% CI, 1.05-1.10; P = 3 × 10-12), coronary artery disease (CAD) (OR: 1.03; 95% CI, 1.01-1.04; P = 0.0029), and marked androgenic alopecia (OR: 1.03; 95% CI, 1.02-1.05; P = 3 × 10-5). Body mass index (BMI), hemoglobin A1c, triglycerides, and free androgen index increased as the PRS increased, whereas high-density lipoprotein cholesterol and SHBG decreased (all P < .0001). The association between the PRS and CAD appeared to be completely mediated by BMI, whereas the associations with T2DM and marked androgenic alopecia appeared to be partially mediated by BMI. Conclusions Genetic risk factors for PCOS have phenotypic consequences in men, indicating that they can act independently of ovarian function. Thus, PCOS in women may not always be a primary disorder of the ovaries.

15 July 2019 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JZJia Zhu
Jia Zhu
LVLisa K. Volkening
Lisa K. Volkening
LLLori M. Laffel
Lori M. Laffel
OBJECTIVE: To evaluate glycemia and metrics of glucose variability in youth with type 1 diabetes, and to assess patterns of 24-h glucose variability according to pubertal status. RESEARCH DESIGN AND METHODS: Metrics of glycemia, glucose variability, and glucose patterns were assessed by using 4 weeks of continuous glucose monitoring (CGM) data from 107 youth aged 8–17 years with type 1 diabetes for ≥1 year. Glucose values per hour were expressed as percentages relative to the mean glucose over 24 h for a 4-week period. Glucose data were compared on the basis of pubertal status—prepubertal (Tanner stage [T] 1), pubertal (T2–4), and postpubertal (T5)—and A1C categories (<7.5% [<58 mmol/mol], ≥7.5% [≥58 mmol/mol]). RESULTS: Youth (50% female, 95% white) had a mean ± SD age of 13.1 ± 2.6 years, diabetes duration of 6.3 ± 3.5 years, and A1C of 7.8 ± 0.8% (62 ± 9 mmol/mol); 88% were pump treated. Prepubertal youth had a higher mean glucose SD (86 ± 12 mg/dL [4.8 ± 0.7 mmol/L]; P = 0.01) and coefficient of variation (CV) (43 ± 5%; P = 0.06) than did pubertal (SD 79 ± 13 mg/dL [4.4 ± 0.7 mmol/L]; CV 41 ± 5%) and postpubertal (SD 77 ± 14 mg/dL [4.3 ± 0.8 mmol/L]; CV 40 ± 5%) youth. Over 24 h, prepubertal youth had the largest excursions from mean glucose and the highest CV across most hours compared with pubertal and postpubertal youth. Across all youth, CV was strongly correlated with the percentage of time with glucose <70 mg/dL (<3.9 mmol/L) (r = 0.79; P < 0.0001). CONCLUSIONS: Prepubertal youth had greater glucose variability independent of A1C than did pubertal and postpubertal youth. A1C alone does not capture the full range of glycemic parameters, highlighting the added insight of CGM in managing youth with type 1 diabetes.

23 April 2026 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LMLoes M. E. Moolhuijsen
Loes M. E. Moolhuijsen
JZJia Zhu
Jia Zhu
BMBenjamin Mullin
Benjamin Mullin
NPNatàlia Pujol-Gualdo
Natàlia Pujol-Gualdo
KAKy'Era Actkins
Ky'Era Actkins
FDFelix R. Day
Felix R. Day
Polycystic ovary syndrome (PCOS) and its underlying features remain poorly understood. In this genetic study ( n = 544,513), we expand the number of genetic loci from 16 to 29, and additionally identify 31 associated plasma proteins. Many risk-increasing loci were associated with later age at menopause, underscoring the reproductive longevity related to an increased oocyte number and/or availability across the lifespan. Hormonal regulation in the etiology of this condition, through metabolic and reproductive features, was emphasized. The proteomic analysis highlighted metabolic biology known to be related to PCOS. A polygenic risk score (PRS) was associated with adverse cardiometabolic outcomes, with differing relevance of testosterone and body mass index in women and men. Finally, while oligo-anovulation and anovulatory infertility are features of PCOS, we observed no impact of PCOS susceptibility on childlessness. We suggest that PCOS susceptibility confers balanced pleiotropic influences on fertility in women, and life-long adverse metabolic consequences in both sexes.

26 November 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
ATAnna Tidwell
Anna Tidwell
JZJia Zhu
Jia Zhu
TBTess Battiola
Tess Battiola
CWCorrine K Welt
Corrine K Welt
Context: Polycystic ovary syndrome (PCOS) affects 10% of women of reproductive age. The genetic architecture of the disease is emerging, but there is little data exploring the effect of genetic risk on clinical presentation. Objective: We hypothesized that genetic risk loci would influence measurable phenotypic traits. Methods: This retrospective cohort study, conducted at an academic medical center, included women of European ancestry with PCOS (n = 404), as diagnosed by the National Institutes of Health criteria, and controls with regular menses and no hyperandrogenism (n = 408). We identified association between genetic risk variants and measured phenotypic traits using linear regression. Results: In a combined analysis of cases and controls, 2 variants in loci containing the genes PRSS23 (P < .001) and FSHB (P < .001) were associated with gonadotropin levels. Two variants in loci containing NEIL2/GATA4 (P = .002) and CYP3 (P < .001) were associated with androgen levels. Three variants in loci containing SHBG (P = .001), ZBTB16 (P < .001), and CYP3 (P < .001) were associated with ovarian morphology. One variant in the locus containing FTO (P = .001) was associated with hip circumference and was influenced by body mass index. Conclusion: These results demonstrate that PCOS genetic risk variants may influence hormone levels and ovarian morphology and increase the risk of obesity. Increased genetic risk for PCOS appears to drive traits that underly the classical clinical presentation of PCOS.

10 September 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
JZJia Zhu
Jia Zhu
AEAnders U Eliasen
Anders U Eliasen
IAIzzuddin M Aris
Izzuddin M Aris
SSSara E Stinson
Sara E Stinson
JHJens-Christian Holm
Jens-Christian Holm
YCYee-Ming Chan
Yee-Ming Chan
Context Polycystic ovary syndrome (PCOS) has historically been conceptualized as a disorder of the reproductive system in women. However, offspring of women with PCOS begin to show metabolic features of PCOS in childhood, suggestive of childhood manifestations. Objective To identify childhood manifestations of genetic risk for PCOS. Methods We calculated a PCOS polygenic risk score (PRS) for 12 350 girls and boys in 4 pediatric cohorts—ALSPAC (UK), COPSAC (Denmark), Project Viva (USA), and The HOLBÆK Study (Denmark). We tested for association of the PRS with PCOS-related phenotypes throughout childhood and with age at pubarche and age at peak height velocity and meta-analyzed effects across cohorts using fixed-effect models. Results Higher PRS for PCOS was associated with higher body mass index in midchildhood (0.05 kg/m2 increase per 1 SD of PRS, 95% CI 0.03, 0.07, P = 3 × 10−5) and higher risk of obesity in early childhood (OR 1.34, 95% CI 1.13, 1.59, P = .0009); both persisted through late adolescence (P all ≤.03). Higher PCOS PRS was associated with earlier age at pubarche (0.85-month decrease per 1 SD of PRS, 95% CI −1.44, −0.26, P = .005) and younger age at peak height velocity (0.64-month decrease per 1 SD of PRS, 95% CI −0.94, −0.33, P = 4 × 10−5). Conclusion Genetic risk factors for PCOS are associated with alterations in metabolic, growth, and developmental traits in childhood. Thus, PCOS may not simply be a condition that affects women of reproductive age but, rather, a possible manifestation of an underlying condition that affects both sexes starting in early life.